BENEFIT Act of 2023
- Last Action
- 2/24/2023
Actions
- 2023-02-24Referred to the Subcommittee on Health.
- 2023-02-17Referred to the House Committee on Energy and Commerce.
- 2023-02-17Introduced in House
- 2023-02-17Introduced in House
CRS Summary
As of 2023-02-17 (00)
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 or the BENEFIT Act of 2023
This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.
After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.
Cosponsors (20)
- Brad Wenstrup (R-OH)
- Gus Bilirakis (R-FL)
- Chellie Pingree (D-ME)
- Rudy Yakym (R-IN)
- Mark Green (R-TN)
- Deborah Ross (D-NC)
- Tim Burchett (R-TN)
- Jared Golden (D-ME)
- Susan Wild (D-PA)
- Don Bacon (R-NE)
- Emanuel Cleaver (D-MO)
- Tony Cárdenas (D-CA)
- Josh Harder (D-CA)
- Brian Fitzpatrick (R-PA)
- Shri Thanedar (D-MI)
- Brian Higgins (D-NY)
- ELEANOR NORTON (D-DC)
- Dean Phillips (D-MN)
- Tom Cole (R-OK)
- Josh Gottheimer (D-NJ)
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.